Pyxis Oncology Inc [PYXS] stock is trading at $3.92, up 1.82%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PYXS shares have gain 3.98% over the last week, with a monthly amount glided 22.50%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, BTIG Research started tracking the stock with Buy rating on February 09, 2024, and set its price target to $8. On January 23, 2024, Leerink Partners initiated with a Outperform rating and assigned a price target of $12 on the stock. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $7 on September 05, 2023. Jefferies initiated its recommendation with a Buy and recommended $25 as its price target on November 02, 2021. Credit Suisse started tracking with a Outperform rating for this stock on November 02, 2021, and assigned it a price target of $19. In a note dated November 02, 2021, BofA Securities initiated an Neutral rating and provided a target price of $16 on this stock.
Pyxis Oncology Inc [PYXS] stock has fluctuated between $1.35 and $6.85 over the past year. Currently, Wall Street analysts expect the stock to reach $10 within the next 12 months. Pyxis Oncology Inc [NASDAQ: PYXS] shares were valued at $3.92 at the most recent close of the market. An investor can expect a potential return of 155.1% based on the average PYXS price forecast.
Analyzing the PYXS fundamentals
Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -3.42%, Pretax Profit Margin comes in at -2.95%, and Net Profit Margin reading is -2.95%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.39 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.75 points at the first support level, and at 3.57 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.08, and for the 2nd resistance point, it is at 4.23.
Ratios To Look Out For
For context, Pyxis Oncology Inc’s Current Ratio is 12.19. Further, the Quick Ratio stands at 12.19, while the Cash Ratio is 2.08. Considering the valuation of this stock, the price to sales ratio is 14.29, the price to book ratio is 1.25.
Transactions by insiders
Recent insider trading involved Connealy Pamela Ann, CFO and COO, that happened on Sep 28 ’23 when 8000.0 shares were purchased. CFO and COO, Connealy Pamela Ann completed a deal on Sep 27 ’23 to buy 6426.0 shares. Meanwhile, Chief Accounting Officer Wadhane Jitendra bought 2500.0 shares on Sep 27 ’23.
